Genprex, Inc. shares were up more than 78% in overnight trading. Genprex said Tuesday a safety review committee approved the increase in dosage to the maximum level of 0.12 mg/kg in the phase 1 trial of its drug candidate, Reqorsa, to treat small-cell lung cancer.

Genprex share skyrocketed 262.57% on Monday.

The "escalation to the highest dose group" comes after the company completed giving the 0.09 mg/kg dose to participants in the Acclaim-3 clinical trial of Reqorsa in combination with atezolizumab, which is sold under the Tecentriq brand name of Genentech.

The trial has not resulted in "dose limiting toxicities" in the 0.09 mg/kg dose group, demonstrating the drug's safety profile, the company said.

The phase 1 trial's primary endpoint is determining the maximum tolerated or recommended phase 2 dose. The phase 2 portion's primary endpoint is to establish the 18-week progression-free survival rate from the time the maintenance therapy begins, Genprex said.

Logitech shares gained 3.6% in overnight trading. Logitech International raised its full-year outlook after a strong performance in the second quarter, the computer keyboard and mouse maker said on Tuesday.

The Swiss-American tech company now expects its full-year sales in the range of $4.39 billion to $4.47 billion.

SAP shares rose 3% in overnight trading. SAP posted higher revenue and profit in the third quarter boosted by artificial-intelligence demand, and raised its full-year outlook.

Reporting on a non-IFRS basis, the German business-software company said total revenue rose 9% to 8.47 billion euros (US $9.21 billion). Revenue from cloud and software climbed to EUR7.43 billion from EUR6.68 billion a year earlier.